Navigation Links
Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Date:3/13/2008

An Innovative Chronic Dialysis Catheter With Patented Triple Arterial Lumen

Design

VANCOUVER, March 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it will introduce and exhibit its innovative HemoStream(TM) chronic dialysis catheter at the 2008 Society of Interventional Radiology (SIR) Annual Scientific Meeting to be held in Washington, DC from March 15-18, 2008.

"It's exciting to participate at SIR and showcase the addition of another 'best-in-class' device offered by Angiotech. We also anticipate that the HemoStream(TM) could be a great candidate for our combination drug-device technologies, such as Angiotech's innovative 5-FU anti-infective platform," said George Leondis, General Manager, Angiotech Interventional.

Incidences of End Stage Renal Disease (ESRD) requiring dialysis are a rapidly growing challenge in healthcare worldwide. When kidneys fail, function of the kidneys can be partially replaced using a process called hemodialysis. Hemodialysis involves drawing blood out of the body, filtering it through a large machine and then returning filtered blood back to the body. Chronic dialysis catheters, such as HemoStream(TM), are used as long term vascular access for hemodialysis. HemoStream may also be used as a temporary access while more permanent options mature or become ready for use, such as a surgically created AV fistula.

A dialysis catheter, such as HemoStream(TM), is used for vascular access and is a vital connection between the patient and the hemodialysis unit. When kidneys fail, the function of the kidneys can be partially replaced using a process called hemodialysis. Hemodialysis involves drawing blood
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... present a company update at the Morgan Stanley Healthcare Conference in New ... , , Interested parties may access a live ... BioMarin website, www.BMRN.com . A replay of the ...
... , NEW BRUNSWICK, N.J., Sept. 8 ... SNT ) today announced that the Company will be presenting at ... held at the New York Palace Hotel from September 9th - ... will deliver the Company,s corporate presentation on Friday, September 11th, at ...
... CAMBRIDGE, Massachusetts, September 8 Shire plc,(LSE: SHP, ... company, is,committed to doing everything possible to assist Gaucher ... is pleased to be,able to provide velaglucerase alfa well ... wide. , In the U.S., ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference 2Update on velaglucerase alfa 2Update on velaglucerase alfa 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... of the American Medical Society ("Medical News & ... Associate Professor Sergei Adamovich, a biomedical engineer. Adamovich and ... and Eugene Tunik, PhD, PT, at the University of ... robotic and virtual reality-based video game therapies to help ...
... that the animal with the most genes--about 31,000--is the ... By comparison, humans have about 23,000 genes. Daphnia is ... The water flea,s genome is described in a ... the Daphnia Genomics Consortium, an international network of scientists ...
... provided the first conclusive evidence that cannabis use significantly hastens ... brain development with possible life-long consequences. The ... smoking cannabis is associated with an earlier onset of psychotic ... an international team including Dr Matthew Large, from the University ...
Cached Biology News:JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3The most genes in an animal? Tiny crustacean holds the record 2The most genes in an animal? Tiny crustacean holds the record 3Cannabis linked to earlier onset of psychosis 2
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: